Response by Fauchier et al to Letter Regarding Article, "Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?"

Affiliations

¹ Service de Cardiologie Centre Hospitalier Universitaire Trousseau et Faculté de Médecine Université François Rabelais Tours, France.
² University of Birmingham Institute of Cardiovascular Sciences City Hospital Birmingham B18 7QH United Kingdom.

Comment

Laurent Fauchier et al. Stroke. 2016 Oct.

. 2016 Oct;47(10):e239.

doi: 10.1161/STROKEAHA.116.014619. Epub 2016 Aug 11.

¹ Service de Cardiologie Centre Hospitalier Universitaire Trousseau et Faculté de Médecine Université François Rabelais Tours, France.
² University of Birmingham Institute of Cardiovascular Sciences City Hospital Birmingham B18 7QH United Kingdom.

No abstract available

Comment on

Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?
Fauchier L, Clementy N, Bisson A, Ivanes F, Angoulvant D, Babuty D, Lip GY. Fauchier L, et al. Stroke. 2016 Jul;47(7):1831-6. doi: 10.1161/STROKEAHA.116.013253. Epub 2016 May 26. Stroke. 2016. PMID: 27231269
Letter by Zhang et al Regarding Article, "Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?".
Zhang H, Hao YG, Xu G. Zhang H, et al. Stroke. 2016 Oct;47(10):e238. doi: 10.1161/STROKEAHA.116.014301. Epub 2016 Aug 11. Stroke. 2016. PMID: 27515843 No abstract available.